Reporter brief
SGLT2 inhibitors associated with reduced heart failure and mortality after heart attack in preserved ejection fraction patients
What happened
This retrospective cohort study of 230 AMI-PCI patients with preserved ejection fraction (LVEF ≥50%) compared outcomes in those prescribed SGLT2 inhibitors versus no SGLT2 inhibitors. After propensity score matching, SGLT2i use was associated with lower rates of new-onset heart failure (6.09% vs 15.65%), all-cause mortality (3.48% vs 10.43%), cardiovascular mortality (1.74% vs 9.57%), and MACE (7.83% vs 18.26%) over at least 18 months follow-up.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Cohort; Human.
Patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI) with preserved left ventricular ejection fraction (LVEF ≥ 50%) and no prior heart failure history
- Design
- Cohort
- Sample
- 230
- Journal
- American journal of translational research
- Published
- Aug 15, 2026
Effect size
For new-onset HF: 6.09% vs. 15.65%, P=0.020; for all-cause mortality: 3.48% vs. 10.43%, P=0.038; for cardiovascular mortality: 1.74% vs. 9.57%, P=0.010; for MACE: 7.83% vs. 18.26%, P=0.019. Multivariable Cox regression: HR 0.583 (95% CI, 0.371-0.916; P=0.017)
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the SGLT2 inhibitors timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.